Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

174
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
174
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

215
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
215
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

256
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
256
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

192
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
192
Inflammatory Response01:28

Inflammatory Response

5.3K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
5.3K
Methods of reducing fever01:22

Methods of reducing fever

732
The signs and symptoms of fever include hot and dry skin, flushed face, thirst, muscle aches, anorexia, headache, tachycardia, tachypnea, and fatigue. Elevated body temperature is reduced using two methods: pharmacological and nonpharmacological. Proper identification and treatment of the root cause of a fever is of utmost importance.
Pharmacological Methods of Reducing Fever:
732

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 public health and social measures (PHSM) and early childhood developmental concerns in Scotland: an interrupted time series analysis.

The Lancet regional health. Europe·2026
Same author

Intraindividual variability, how do I measure thee? Let me count the ways.

The Clinical neuropsychologist·2025
Same author

The state of science convergence in implantable brain-computer interface clinical trials.

Journal of neural engineering·2025
Same author

Antenatal Corticosteroids and Infectious Diseases Throughout Childhood.

JAMA network open·2025
Same author

ABO blood group antigens influence host-microbe interactions and risk of early spontaneous preterm birth.

NPJ biofilms and microbiomes·2025
Same author

Effect of caesarean birth on perinatal mortality for singleton breech presentation in spontaneous preterm labour-A target trial emulation using Scottish health record data.

PloS one·2025
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026
Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Aug 28, 2025

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development
08:50

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development

Published on: June 24, 2020

3.8K

Preterm Birth Therapies to Target Inflammation.

Ioannis Pavlidis1, Sarah J Stock2

  • 1University of Warwick Biomedical Research Unit in Reproductive Health, Coventry, UK.

Journal of Clinical Pharmacology
|September 15, 2022
PubMed
Summary
This summary is machine-generated.

Preterm birth (PTB) prevention and treatment remain challenging due to limited therapies. Targeting inflammation in gestational tissues offers promising new strategies for managing PTB and its complications.

Keywords:
inflammationobstetricspreterm birththerapeuticswomen's health

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.4K
A Preterm Rat Model for Pain Studies
01:37

A Preterm Rat Model for Pain Studies

Published on: February 9, 2024

468

Related Experiment Videos

Last Updated: Aug 28, 2025

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development
08:50

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development

Published on: June 24, 2020

3.8K
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.4K
A Preterm Rat Model for Pain Studies
01:37

A Preterm Rat Model for Pain Studies

Published on: February 9, 2024

468

Area of Science:

  • Reproductive biology
  • Immunology
  • Perinatology

Background:

  • Preterm birth (PTB) is a leading cause of infant mortality.
  • Limited therapeutic options exist for PTB prevention and treatment.
  • Inflammation in gestational tissues is a key factor in PTB pathophysiology.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for PTB.
  • To discuss therapies targeting inflammatory pathways involved in PTB.

Main Methods:

  • Review of traditional therapies for PTB.
  • Highlighting novel preclinical approaches targeting inflammatory mediators.
  • Discussion of mechanistic studies on PTB pathophysiology.

Main Results:

  • Inflammation, even without infection, can trigger parturition.
  • Several therapeutic targets within inflammatory pathways have been identified.
  • Both established and novel therapeutic approaches show potential.

Conclusions:

  • Effective PTB prevention and treatment strategies are urgently needed.
  • Targeting inflammation offers a promising avenue for PTB management.
  • Collaborative efforts are essential to address the challenge of PTB.